5Treatment of hematological malignancies with nonmyeloablative, HLA-haploidentical bone marrow transplantation and high dose, post-transplantation cyclophosphamide
Introduction
Allogeneic stem cell transplantation, or alloSCT, is a potentially curative option for many patients with hematological malignancies, particularly those with cytogenetically standard or poor risk acute leukemia in remission [1]. Historically the curative potential of alloSCT was ascribed to the eradication of the malignancy by lethal doses of chemotherapy with or without radiation, and the bone marrow infusion “rescued” the patient from otherwise fatal marrow aplasia. However it is now quite apparent that an important mechanism of cure in alloSCT is the graft-versus-leukemia, or GVL, effect [2]. Donor T-cells contained in the graft are likely responsible for the GVL effect. Unfortunately, donor T-cells also play a significant role in graft-versus-host disease (GVHD), a major contributor to non-relapse mortality (NRM). The goal in alloSCT is to develop a way to maximize the graft-versus-tumor (GVT) effect while minimizing GVHD, graft failure, NRM, and relapse. We continue to search for the best combination of donor, conditioning regimen, and post-transplantation immunosuppression to achieve those goals.
Section snippets
Nonmyeloablative conditioning regimens
There has been increasing experience with the use of nonmyeloablative conditioning regimens prior to alloSCT. These regimens typically incorporate highly immunosuppressive but moderately myelosuppressive chemotherapy followed by high stem cell doses and post-transplantation pharmacologic immunosuppression. The principles underlying the use of nonmyeloablative conditioning [3] are: (1) immunosuppression should be sufficient to allow donor engraftment; (2) a high dose of donor stem cells
HLA-haploidentical stem cell transplantation
Most experience with alloSCT has been with matched sibling donors. However, only about 30% of patients have a matched sibling making it necessary to identify alternative donors. The National Marrow Donor Program (NMDP) was initiated in 1986 to create a network “to facilitate successful transplants of hematopoietic stem cells from volunteer unrelated donors as lifesaving therapy for patients of all racial and socioeconomic backgrounds.” Finding potential matched unrelated donors has proven to
Drug-induced immunological tolerance
The idea of giving post-transplantation cyclophosphamide came from studies that have shown that a properly timed, high dose of cyclophosphamide induces immunological tolerance. Drug-induced immunological tolerance is not a new concept. It was initially reported in 1959 when it was shown that giving rabbits 6-mercaptopurine prevented their ability to produce antibodies against human serum albumin [30].
Through a progression of studies it was found that cyclophosphamide given one to three days
Phase I trial of nonmyeloablative, HLA-haploidentical BMT with high dose, post-transplantation cyclophosphamide
Based on the results of our mouse data we completed a phase I clinical trial to determine the minimal conditioning, including post-transplantation cyclophosphamide which permitted stable engraftment of partially HLA-mismatched marrow from first-degree relatives [43]. All patients had high-risk hematological malignancies and were not eligible for standard alloSCT. The preparative regimen initially consisted of fludarabine and total body irradiation (TBI). GVHD prophylaxis consisted of high-dose
Phase II trial of nonmyeloablative, HLA-haploidentical BMT with high dose post-transplantation cyclophosphamide
Because of the encouraging results of our phase I clinical trial we designed a phase II clinical trial. We provide here an update on data that have previously been reported *[44], *[45]. As of September 14, 2010, 210 consecutive patients received nonmyeloablative, HLA-haploidentical transplantation with high-dose, post-transplantation cyclophosphamide and had at least one year of follow-up. Details concerning criteria for eligibility, HLA typing, transplantation procedure, and outcomes
Discussion
Our data suggest that nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide is a safe alternative for patients with hematological malignancies without suitable donors or with co-morbidites that would preclude them from receiving a myeloablative transplant. It allows for transplantation to occur more quickly in patients in whom the disease is too advanced or aggressive to wait for a suitable matched unrelated donor to be found.
Conflict of interest
The authors declare no conflicts of interest.
Acknowledgments
Supported by P01 CA15396 from the National Cancer Institute.
References (54)
- et al.
Graft-versus-leukemia reactions after bone marrow transplantation
Blood
(1990) - et al.
HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies
Blood
(2003) - et al.
Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: current perspectives
Biol Blood Marrow Transplant
(2007) - et al.
Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors
Blood
(2004) - et al.
Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities
Blood
(2004) - et al.
Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991–2000)
Blood
(2003) - et al.
High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma
Biol Blood Marrow Transplant
(2008) - et al.
transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose
Blood
(1997) - et al.
The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation
Blood
(2001) - et al.
T-cell depletion of HLA-identical transplants in leukemia
Blood
(1991)
Immune reconstitution following bone marrow transplantation: comparison of recipients of T-cell depleted marrow with recipients of conventional marrow grafts
Blood
Interleukin-2 production and response to interleukin-2 by peripheral blood mononuclear cells from patients after bone marrow transplantation: II. Patients receiving soybean lectin-separated and T cell-depleted bone marrow
Blood
Reconstitution of T-cell function after CD6-depleted allogeneic bone marrow transplantation
Blood
Analysis of T-cell repopulation after allogeneic bone marrow transplantation: significant differences between recipients of T-cell depleted and unmanipulated grafts
Blood
Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide
Blood
Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide
Biol Blood Marrow Transplant
Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome
Biol Blood Marrow Transplant
HLA-Haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide
Biol Blood Marrow Transplant
Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma
Hum Immunol
Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation
Biol Blood Marrow Transplant
Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation
Blood
Nonmyeloablative allogeneic hematopoietic stem cell transplant using mismatched/haploidentical donors: a review
Blood Cells Mol Dis
Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced intensity conditioning regimens
Crit Rev Oncology/Hematology
Nonengraftment haploidentical cellular immunotherapy for refractory malignancies: tumor responses without chimerism
Biol Blood Marrow Transplant
Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials
JAMA: J Am Med Assoc
Non-myeloablative stem cell transplants
Br J Haematol
Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning
J Clin Oncol
Cited by (44)
Bone marrow versus peripheral blood as a graft source for haploidentical donor transplantation in adults using post-transplant cyclophosphamide—A systematic review and meta-analysis
2019, Critical Reviews in Oncology/HematologyCitation Excerpt :The pooled OS of single-arm BM and PB studies were 0.543 (95%CI, 0.453-0.632) and 0.591 (95%CI, 0.470-0.713), respectively. Twelve studies (Bashey et al., 2017; Bradstock et al., 2015; O’Donnell et al., 2016; Cieri et al., 2015; Sugita et al., 2015; Solomon et al., 2015a,b; Raj et al., 2014; Munchel et al., 2011; Ciurea et al., 2012; Gaballa et al., 2016a,b; McCurdy et al., 2017; Raiola et al., 2014) reported data on the 2-year DFS involving a total of 1709 patients. Based on the data given, no evidence supported that transplantation with BM improved 2-year DFS compared to transplantation with PB.
Current Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphocytic Leukemia: Success, Failure and Future Perspectives—A Single-Center Experience, 2008 to 2016
2018, Biology of Blood and Marrow TransplantationCurative approaches for sickle cell disease: A review of allogeneic and autologous strategies
2017, Blood Cells, Molecules, and Diseases